Bioporto: Wrap up from yesterday's event
Today, we hosted an event with Bioporto, where the company’s SVP for Global Marketing & US Commercialization, Jennifer Zonderman, and CFO Niels Høj Nielsen participated. The focus of the event was on 'building the global commercial platform.'
SVP Jennifer Zonderman provided in-depth insights into the operational initiatives the company is undertaking to bring NGAL from research to clinical testing.
In addition to discussing the competitors Bioporto faces and the market structure, SVP Jennifer Zonderman explained why NGAL is unique in the context of AKI. For the first time, investors gained a deeper understanding of how the company is progressing not only in the crucial US market but also in the rest of the world (ROW).
Listen to the interview here: Interview with Bioporto
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:50 AM 23-10-2024.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Lue lisää yhtiösivulla